TapewireFind a company

person · Reporting owner

Dunne Michael W.

Disclosed activity across 2 companies

Tapewire entity
72803
SEC CIK
0001553593

Export transaction history ↓

Reported relationships

Latest disclosed role at each company.

CompanyLast reported asReport datePublished
Iterum Therapeutics plcITRM · Entity 72802DirectorNovember 18, 2025November 20, 2025
Vaxart, Inc.AVIR · Entity 6654DirectorMay 18, 2017May 22, 2017

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Iterum Therapeutics plc

Report date November 18, 2025 · Filed November 20, 2025

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Ordinary SharesSEC Table I · non-derivativeDirect241,001 Reported balance After 2025-11-18 transaction · row 1
1 source row

Row 1 · 2025-11-18 · Purchase · Acquired 6,000 · Balance 241,001

Vaxart, Inc.

Report date May 18, 2017 · Filed May 22, 2017

Security / awardOwnership accountDisclosed shares / unitsDisclosure context
Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.49 · Expires 2027-05-18Direct75,000 Reported balance After 2017-05-18 transaction · row 1 Instrument identity requires review; Table II rows are not merged.
1 source row

Row 1 · 2017-05-18 · Grant · Acquired 20,000 · Balance 75,000

Transaction history

JSON API
Reset

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction dateCompanyActivity / securityShares / unitsReported priceReported valueDetails
November 18, 2025 Filed Nov 20, 2025 07:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 6,000 $0.37 $2,191.20
Disclosure

SEC source: 0001193125-25-288848 · ownership.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 241,001

Read SEC document
August 08, 2025 Filed Aug 12, 2025 07:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 15,000 $0.72 $10,854.00
Disclosure

SEC source: 0000950170-25-106908 · ownership.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 235,001

Read SEC document
August 06, 2024 Filed Aug 12, 2024 09:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionWarrants (right to buy) · Derivative 106,247 Not disclosed Strike: $1.21 Not disclosed
Disclosure

SEC source: 0000950170-24-095096 · ownership.xml · derivative · entry 4

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,247

Underlying: Ordinary Shares · 106,247 shares

Expires 2029-08-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").

Read SEC document
August 06, 2024 Filed Aug 12, 2024 09:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionWarrants (right to buy) · Derivative 106,247 Not disclosed Strike: $1.21 Not disclosed
Disclosure

SEC source: 0000950170-24-095096 · ownership.xml · derivative · entry 3

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 106,247

Underlying: Ordinary Shares · 53,123 shares

Expires 2025-08-09

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").

Read SEC document
August 06, 2024 Filed Aug 12, 2024 09:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionSubscription Rights (right to buy) · Derivative 212,494 $0.00 Strike: $0.61 $0.00
Disclosure

SEC source: 0000950170-24-095096 · ownership.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Units · Not disclosed shares

Expires 2024-08-06

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.underlying_shares: The Reporting Person validly exercised 212,494 subscription rights to acquire 106,247 units composed of (i) 106,247 ordinary shares, (ii) 106,247 1-year warrants and (iii) 106,247 5-year warrants.

Read SEC document
August 06, 2024 Filed Aug 12, 2024 09:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 106,247 Not disclosed Not disclosed
Disclosure

SEC source: 0000950170-24-095096 · ownership.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 220,001

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The reported securities were purchased in the Issuer's rights offering (the "Offering") which closed on August 9, 2024. As part of the Offering, the Reporting Person purchased 106,247 units at a subscription price of $1.21 per whole unit. Each unit consisted of (a) one ordinary share, (b) a warrant to purchase 0.50 ordinary shares, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration one year from the date of issuance ("1-year warrants"), and (c) a warrant to purchase one ordinary share, at an exercise price of $1.21 per whole ordinary share from the date of issuance through its expiration five years from the date of issuance ("5-year warrants").

Read SEC document
December 22, 2023 Filed Dec 27, 2023 09:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 25,000 $1.40 $35,000.00
Disclosure

SEC source: 0001209191-23-059750 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 113,754

Read SEC document
December 18, 2023 Filed Dec 19, 2023 16:15 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 10,000 $1.84 $18,442.00
Disclosure

SEC source: 0001209191-23-059133 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 88,754

F1 · price: The price reported is a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $1.795 to $1.85. The Reporting Person undertakes to provide upon request of the SEC staff, the Issuer, or any shareholder of the Issuer, full information requiring the number of securities purchased at each separate price within the range set forth in this footnote.

Read SEC document
November 22, 2023 Filed Nov 27, 2023 17:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 20,000 $2.03 $40,690.00
Disclosure

SEC source: 0001209191-23-056685 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 78,754

F1 · price: The price reported is a weighted average price. The securities were purchased in multiple transactions at per share prices ranging from $1.93 to $2.11. The Reporting Person undertakes to provide upon request the SEC staff, the Issuer, or any shareholder of the Issuer, full information regarding the number of securities purchased at each separate price within the range set forth in this footnote.

Read SEC document
October 01, 2023 Filed Oct 2, 2023 09:20 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 3,487 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-050911 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 3,487 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · derivative.exercise_date: On December 23, 2022, the reporting person was granted an award of 3,487 RSUs, which vested in full on October 1, 2023.

F2 · derivative.expiration_date: On December 23, 2022, the reporting person was granted an award of 3,487 RSUs, which vested in full on October 1, 2023.

Read SEC document
October 01, 2023 Filed Oct 2, 2023 09:20 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 3,487 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-050911 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 58,754

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
July 01, 2023 Filed Jul 3, 2023 08:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 1,779 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-040406 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,779 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · derivative.exercise_date: On September 25, 2022, the reporting person was granted an award of 1,799 RSUs, which vested in full on July 1, 2023.

F2 · derivative.expiration_date: On September 25, 2022, the reporting person was granted an award of 1,799 RSUs, which vested in full on July 1, 2023.

Read SEC document
July 01, 2023 Filed Jul 3, 2023 08:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 1,779 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-040406 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 55,267

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
June 15, 2023 Filed Jun 15, 2023 17:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 15,853 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-037407 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 15,853 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · derivative.exercise_date: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023.

F2 · derivative.expiration_date: On June 15, 2022, the reporting person was granted an award of 15,853 RSUs, which vested in full on June 15, 2023.

F3 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

Read SEC document
June 15, 2023 Filed Jun 15, 2023 17:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 15,853 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-037407 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 53,488

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
April 01, 2023 Filed Apr 3, 2023 20:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 1,299 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-022422 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 1,299 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · derivative.exercise_date: On June 25, 2022, the reporting person was granted an award of 1,299 RSUs, which vested in full on April 1, 2023.

F2 · derivative.expiration_date: On June 25, 2022, the reporting person was granted an award of 1,299 RSUs, which vested in full on April 1, 2023.

F3 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported in this Form 4 have been adjusted to reflect the Reverse Share Split.

Read SEC document
April 01, 2023 Filed Apr 3, 2023 20:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 1,299 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-022422 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,636

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
April 01, 2023 Filed Jun 5, 2023 08:00 UTC Amendment Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 1,299 $0.00 $0.00
Disclosure

SEC source: 0001209191-23-034106 · doc4a.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 37,635

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · balance_after: This amendment is being filed solely to correct an error in the Amount of Securities Beneficially Owned Following Reported Transaction in the original Form 4, as filed on April 3, 2023. The Amount of Securities Beneficially Owned Following Reported Transaction on April 1, 2023, which were reported as 37,636, should have been reported as 37,635.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 18:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 761 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-23-001287 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 761 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · derivative.exercise_date: On March 25, 2022, the reporting person was granted an award of 11,426 RSUs (the "RSU Grant"), which vested on January 1, 2023.

F2 · derivative.expiration_date: On March 25, 2022, the reporting person was granted an award of 11,426 RSUs (the "RSU Grant"), which vested on January 1, 2023.

F3 · derivative.underlying_shares: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares underlying the RSU Grant have been adjusted to reflect the Reverse Share Split.

Read SEC document
January 01, 2023 Filed Jan 4, 2023 18:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 761 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-23-001287 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,337

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
December 23, 2022 Filed Dec 28, 2022 21:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Share Units · Derivative 3,487 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-062871 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 3,487

Underlying: Ordinary Shares · 3,487 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on October 1, 2023.

Read SEC document
September 25, 2022 Filed Sep 27, 2022 21:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Share Units · Derivative 1,779 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-051416 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 1,779

Underlying: Ordinary Shares · 1,779 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated 2018 Equity Incentive Plan, as amended, the RSUs shall vest in full on July 1, 2023.

Read SEC document
September 07, 2022 Filed Sep 9, 2022 18:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 10,000 $2.22 $22,200.00
Disclosure

SEC source: 0001209191-22-049352 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 35,576

F1 · balance_after: On August 17, 2022 the Issuer effected a 1 for 15 reverse share split (the "Reverse Share Split"). The number of ordinary shares reported on this Form 4 have been adjusted to reflect the Reverse Share Split.

Read SEC document
June 25, 2022 Filed Jun 28, 2022 21:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Share Units · Derivative 19,488 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-039706 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 19,488

Underlying: Ordinary Shares · 19,488 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on April 1, 2023.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on April 1, 2023.

Read SEC document
June 23, 2022 Filed Jun 24, 2022 18:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 36,798 $0.00 Strike: $0.00 $0.00
Disclosure

SEC source: 0001209191-22-039312 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 36,798 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

F2 · derivative.exercise_date: On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022.

F2 · derivative.expiration_date: On June 23, 2021, the reporting person was granted an award of 36,798 RSUs, which vested on June 23, 2022.

Read SEC document
June 23, 2022 Filed Jun 24, 2022 18:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 36,798 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-22-039312 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 383,647

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the RSUs.

Read SEC document
June 15, 2022 Filed Jun 17, 2022 17:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Share Units · Derivative 237,795 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-037937 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 237,795

Underlying: Ordinary Shares · 237,795 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 15, 2023.

Read SEC document
March 25, 2022 Filed Mar 29, 2022 20:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Share Units · Derivative 11,426 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-021542 · doc4.xml · derivative · entry 3

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 11,426

Underlying: Ordinary Shares · 11,426 shares

Expires not disclosed

F3 · derivative.exercise_price: Each restricted share unit ("2022 RSU") represents the contingent right to receive one ordinary share upon vesting of a 2022 RSU.

F4 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the 2022 RSUs shall vest in full on January 1, 2023.

F4 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the 2022 RSUs shall vest in full on January 1, 2023.

Read SEC document
March 25, 2022 Filed Mar 29, 2022 20:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionRestricted Share Units · Derivative 10,494 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-021542 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 10,494 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Restricted share units ("2021 RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the 2021 RSUs.

F2 · derivative.exercise_date: On March 25, 2021, the reporting person was granted an award of 10,494 2021 RSUs, which vested on March 25, 2022.

F2 · derivative.expiration_date: On March 25, 2021, the reporting person was granted an award of 10,494 2021 RSUs, which vested on March 25, 2022.

Read SEC document
March 25, 2022 Filed Mar 29, 2022 20:00 UTC Iterum Therapeutics plc ITRM · Entity 72802 Exercise / conversionOrdinary Shares 10,494 $0.00 $0.00
Disclosure

SEC source: 0001209191-22-021542 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 346,849

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: Restricted share units ("2021 RSUs") converted into ordinary shares on a one-for-one basis upon vesting of the 2021 RSUs.

Read SEC document
July 25, 2021 Filed Jul 27, 2021 21:30 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantOrdinary Shares 80,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-030223 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 336,355

F1 · shares: Consists of 80,000 ordinary shares received upon vesting of performance-based stock units ("PSUs") on July 25, 2021, which PSUs were subject to performance conditions that have been satisfied. PSUs convert into ordinary shares on a one-for-one basis.

Read SEC document
June 23, 2021 Filed Jun 25, 2021 16:05 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Stock Units · Derivative 36,798 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-025953 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 36,798

Underlying: Ordinary Shares · 36,798 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, as amended, the RSUs shall vest in full on June 23, 2022.

Read SEC document
March 25, 2021 Filed Mar 29, 2021 17:33 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantRestricted Stock Units · Derivative 10,494 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-013822 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 10,494

Underlying: Ordinary Shares · 10,494 shares

Expires not disclosed

F1 · derivative.exercise_price: Each restricted share unit ("RSU") represents the contingent right to receive one ordinary share upon vesting of the RSU.

F2 · derivative.exercise_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest on March 25, 2022.

F2 · derivative.expiration_date: Subject to the reporting person providing continuous service to the Issuer and the other terms and conditions of the Issuer's 2018 Amended and Restated Equity Incentive Plan, the RSUs shall vest on March 25, 2022.

Read SEC document
January 26, 2021 Filed Jan 27, 2021 19:32 UTC Iterum Therapeutics plc ITRM · Entity 72802 SaleOrdinary Shares 33,143 $1.73 $57,337.39
Disclosure

SEC source: 0000899243-21-003519 · doc4.xml · nonDerivative · entry 2

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 256,355

F2 · shares: Represents the shares automatically sold by the reporting person pursuant to an election to satisfy tax withholding obligations in connection with the vesting of the PSUs. This sale does not represent a discretionary trade by the reporting person.

Read SEC document
January 25, 2021 Filed Jan 27, 2021 19:32 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantOrdinary Shares 80,000 $0.00 $0.00
Disclosure

SEC source: 0000899243-21-003519 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 289,498

F1 · shares: Consists of 80,000 ordinary shares received upon vesting of performance-based stock units ("PSUs") on January 25, 2021, which PSUs were subject to performance conditions that have been satisfied. PSUs convert into ordinary shares on a one-for-one basis.

Read SEC document
October 27, 2020 Filed Oct 28, 2020 16:15 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseWarrants (right to buy) · Derivative 46,155 Not disclosed Strike: $0.65 Not disclosed
Disclosure

SEC source: 0000899243-20-029501 · doc4.xml · derivative · entry 2

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 46,155

Underlying: Ordinary Shares · 46,155 shares

Expires 2025-10-27

F1 · price: The reported securities were purchased in the Issuer's registered public offering on October 27, 2020 at a combined purchase price of $0.65 per ordinary share and warrant. Each ordinary share was purchased together with a warrant to purchase 0.75 of an ordinary share.

Read SEC document
October 27, 2020 Filed Oct 28, 2020 16:15 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 61,540 Not disclosed Not disclosed
Disclosure

SEC source: 0000899243-20-029501 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 209,498

F1 · price: The reported securities were purchased in the Issuer's registered public offering on October 27, 2020 at a combined purchase price of $0.65 per ordinary share and warrant. Each ordinary share was purchased together with a warrant to purchase 0.75 of an ordinary share.

Read SEC document
February 15, 2019 Filed Feb 19, 2019 11:34 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantStock Option (Right to Buy) · Derivative 85,000 $0.00 Strike: $5.80 $0.00
Disclosure

SEC source: 0000899243-19-003972 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 85,000

Underlying: Ordinary Shares · 85,000 shares

Expires 2029-02-14

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of February 15, 2019 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.

Read SEC document
September 04, 2018 Filed Sep 6, 2018 17:11 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 500 $10.00 $5,000.00
Disclosure

SEC source: 0001209191-18-049884 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,958

Read SEC document
August 27, 2018 Filed Aug 28, 2018 17:18 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 500 $10.00 $5,000.00
Disclosure

SEC source: 0001209191-18-048708 · doc4.xml · nonDerivative · entry 2

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 147,458

Read SEC document
August 24, 2018 Filed Aug 28, 2018 17:18 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 500 $10.00 $5,000.00
Disclosure

SEC source: 0001209191-18-048708 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,958

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries B-2 Preferred Shares · Derivative 2,917 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · derivative · entry 7

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 2,917 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F3 · derivative.exercise_date: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.expiration_date: Not applicable.

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries B-1 Preferred Shares · Derivative 4,050 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · derivative · entry 6

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 4,050 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F2 · derivative.exercise_date: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.expiration_date: Not applicable.

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionSeries A Preferred Shares · Derivative 12,730 $0.00 $0.00
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · derivative · entry 5

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 0

Underlying: Ordinary Shares · 12,730 shares

Expires not disclosed

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F1 · derivative.exercise_date: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

F4 · derivative.expiration_date: Not applicable.

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 PurchaseOrdinary Shares 2,000 $13.00 $26,000.00
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 4

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 146,458

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 2,917 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 3

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 144,458

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · price: The Series B-2 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 4,050 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 2

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 141,541

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · price: The Series B-1 Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

Read SEC document
May 30, 2018 Filed May 30, 2018 17:02 UTC Iterum Therapeutics plc ITRM · Entity 72802 ConversionOrdinary Shares 12,730 Not disclosed Not disclosed
Disclosure

SEC source: 0001209191-18-034172 · doc4.xml · nonDerivative · entry 1

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 137,491

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · price: The Series A Preferred Shares automatically converted into Ordinary Shares of the Issuer on a 1-to-1 basis upon closing of the initial public offering of the Issuer.

Read SEC document
May 24, 2018 Filed May 29, 2018 17:21 UTC Iterum Therapeutics plc ITRM · Entity 72802 GrantStock Option (Right to Buy) · Derivative 79,567 $0.00 Strike: $13.00 $0.00
Disclosure

SEC source: 0001209191-18-033905 · doc4.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Chief Scientific Officer

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 79,567

Underlying: Ordinary Shares · 79,567 shares

Expires 2028-05-23

F1 · derivative.exercise_date: The shares subject to this option shall vest at a rate of twenty-five percent of the total number of shares on the one-year anniversary of May 24, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares each monthly anniversary of the Vesting Commencement Date thereafter for so long as the Reporting Person provides continuous service to the Issuer, such that the total number of shares shall be fully vested on the four-year anniversary of the Vesting Commencement Date.

Read SEC document
May 18, 2017 Filed May 22, 2017 19:30 UTC Vaxart, Inc. AVIR · Entity 6654 GrantStock Option (Right to Buy) · Derivative 20,000 $0.49 Strike: $0.49 $9,800.00
Disclosure

SEC source: 0001437749-17-009784 · rdgdoc.xml · derivative · entry 1

Dunne Michael W. · CIK 0001553593 · Director

10b5-1 filing: Not disclosed

Ownership: Direct

Disclosed balance after: 75,000

Underlying: Common Stock · 20,000 shares

Expires 2027-05-18

Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.